Both the Neuronal and Inducible Isoforms Contribute to Upregulation of Retinal Nitric Oxide Synthase Activity by Brain-Derived Neurotrophic Factor

Nikolaj Klöcker, Pawel Kermer, Marc Gleichmann, Michael Weller, and Mathias Bähr

Department of Neurology, University of Tübingen, 72076 Tübingen, Germany

Although neurotrophins are best known for their trophic functions, growing evidence suggests that neurotrophins can also be neurotoxic, for instance by enhancing excitotoxic insults. We have shown recently that brain-derived neurotrophic factor (BDNF) limits its neuroprotective action on axotomized rat retinal ganglion cells (RGCs) by upregulating nitric oxide synthase (NOS) activity (Klöcker et al., 1998). The aim of the present study was to investigate this interaction of BDNF and NOS in the lesioned adult rat retina in more detail. We used NOS immunohistochemistry and NADPH-diaphorase (NADPH-d) reaction to characterize morphologically retinal NOS expression and activity. Using reverse transcription-PCR and Western blot analysis, we were able to identify the NOS isoforms being regulated. Six days after optic nerve lesion, we observed an increase in neuronal NOS (NOS-I) mRNA and protein expression in the inner retina. This did not lead to a marked increase in overall retinal NOS activity. Only RGC axons displayed strong de novo NADPH-d reactivity. In contrast, intracocular injection of BDNF resulted in a marked upregulation of NOS activity in NOS-I-immunoreactive structures, leaving the level of NOS-I expression unchanged. In addition, an induction of inducible NOS (NOS-II) was found after BDNF treatment. We identified microglial cells increasing in number and being activated by BDNF, which could serve as the cellular source of NOS-II. In summary, our data suggest that BDNF upregulates retinal NOS activity by both a post-translational regulation of NOS-I activity and an induction of NOS-II. These findings might be useful for developing pharmacological strategies to improve BDNF-mediated neuroprotection.

Key words: BDNF; nitric oxide synthase; NADPH-diaphorase; microglia; retina; axotomy; neurodegeneration

The nerve growth factor (NGF) gene family, referred to as the neurotrophins, comprises a class of highly related proteins, including NGF itself, brain-derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4/5 (Ibañez, 1994). They have been shown to serve as survival, mitogenic, and differentiation factors in both the developing and adult CNS and PNS (Davies, 1994; Barbadic, 1995; Cellerino and Maffei, 1996). Despite the abundance of in vitro and in vivo data demonstrating neuroprotective properties of neurotrophins (for review, see Snider and Johnson, 1989; Lewin and Barde, 1996), recent in vitro evidence provocatively suggested that neurotrophins under certain circumstances can also be neurotoxic by enhancing excitotoxic insults (Koh et al., 1995; Samdani et al., 1997).

Axonal lesions in the adult mammalian CNS often lead to secondary degeneration and death of the injured neurons. Transection of the optic nerve (ON) in the adult rat, for instance, results in retrograde death of 85% of retinal ganglion cells (RGCs) within 14 d (Villegas-Pérez et al., 1988, 1993). Several neurotrophic factors promote survival of axotomized adult RGCs, BDNF being one of the most effective (Mey and Thanos, 1993; Mansour-Robaey et al., 1994; Peinado-Ramón et al., 1996; Klöcker et al., 1997). However, we have shown recently that exogenously applied BDNF limits its neuroprotective potential on axotomized RGCs by increasing retinal nitric oxide synthase (NOS) activity (Klöcker et al., 1998). Work by Cellerino and collaborators demonstrated that retinal NOS activity is reduced in mice deficient for the bdnf gene, thus suggesting a role also for endogenous BDNF in the regulation of retinal NOS activity (Cellerino et al., 1998).

We therefore sought out to investigate the interaction of BDNF and NOS in more detail. Up to now, three isoforms of NOS have been characterized and cloned: neuronal NOS (NOS-I or nNOS), inducible NOS (NOS-II or iNOS), and endothelial NOS (NOS-III or eNOS) (for review, see Marletta, 1994; Nathan and Xie, 1994; Nathan and Xie, 1994; Griffith and Stuehr, 1995). NOS-I and NOS-III are constitutively expressed, whereas NOS-II is usually not expressed but induced in many cell types by certain immunological stimuli (Nathan and Xie, 1994). In the present study, we first used NOS immunohistochemistry and the NADPH-diaphorase (NADPH-d) reaction (Darius et al., 1995) to describe morphologically the effects of BDNF on retinal NOS expression and activity. Using reverse transcription (RT)-PCR and Western blot analysis, we further addressed the question as to which isoform of NOS is regulated by BDNF. Because BDNF is known to enhance glutamatergic neurotransmission (Carmignoto et al., 1997; Jarvis et al., 1997; Sakai et al., 1997; Suen et al., 1997; Lin et al., 1998) and because NOS-I can be regulated post-translationally by increased intracellular calcium (Nathan and Xie, 1994), we also investigated whether BDNF upregulates NOS-I activity by modifying NMDA receptor activation. To this end, we tested whether the NMDA open-channel blocker memantine could reduce BDNF-induced upregulation of NOS activity.
MATERIALS AND METHODS

Animal surgery. Adult female Dark Agouty rats (150–200 gm; Charles River Wiga, Sulzfeld, Germany) were anesthetized by intraperitoneal injection of chloral hydrate (0.42 gm/kg body weight). The right ON was transected as described previously (Klöcker et al., 1998). Briefly, the orbita was opened saving the supraorbital vein, and the lacrimal gland was subtotally resected. By means of a small retractor, the extraocular muscles were spread, and the ON was exposed after longitudinal incision of the eye retractor muscle and the dura sheath. The ON was transected 2 mm from the ocular bulb. After surgery, preservation of the retinal blood supply was checked fundoscopically. To determine RGC densities, cells were retrogradely labeled with the fluorescent tracer Fast Blue (FB) (Dr. Illing Chemie, Gross-Umstadt, Germany). To this end, a small piece of gel foam soaked in 2% aqueous FB was placed at the ocular stump of the ON after transection. For double-labeling experiments (NOS immunohistochemistry and retrograde tracing), we used the fluorescent tracer Fluoro- gold (FG) (Fluochrome Inc., Englewood, CO). In this case, animals were anesthetized by diethyl ether at postnatal day 7, when their superior colliculi offer good surgical access, because they are not yet overgrown by the visual cortex. The skin was incised medially, and the skull cartilage was opened dorsal to the lambda fissure. FG (5% in normal saline) was then applied to both superior colliculi using a microcapillary (Klo¨cker et al., 1998).

Drug administration. Recombinant human BDNF (Alomone Labs, Jerusalem, Israel) was dissolved in a 1% solution of bovine serum albumin (BSA) in PBS at a concentration of 250 ng/µl. Under diethyl ether anesthesia, 2 µl of BDNF (500 ng) in BSA–PBS or 2 µl BSA–PBS without BDNF (vehicle) were injected into the vitreous of the right eye by means of a glass microelectrode with a tip diameter of 30 µm, puncturing the eye at the cornea–sclera junction. BDNF–vehicle treatment consisted of a single injection on day 4 after ON transection.

Memantine hydrochloride was purchased from Merz & Co. (Frankfurt, Germany) and was administered intraperitoneally at a dose of 20 mg/kg body weight every 12 hr starting on the day of surgery. The treatment regimens combining memantine and BDNF consisted of the memantine treatment as described above and either a single intraocular injection of 500 ng of BDNF on day 4 after axotomy for the NADPH-d histochemistry or three intraocular injections of 500 ng of BDNF repeated on days 4, 7, and 10 after axotomy for the neuroprotection study (Klöcker et al., 1998).

RGC densities. Fourteen days after ON transection, animals were killed by an overdose of chloral hydrate, and both eyes were removed. The retinas were dissected, flat-mounted on glass slides, and fixed in 4% paraformaldehyde (PFA) in PBS for 20 min. They were examined by fluorescent microscopy (Axioskop 2; Zeiss, Göttingen, Germany) using an UV filter (365/397 nm) for FB and FG fluorescence. RGC densities were determined as described in detail previously (Kermer et al., 1998; Klo¨cker et al., 1998). Briefly, tracer-labeled RGCs were counted in 12 distinct areas of 62,500 µm² each (three areas per retinal quadrant at three different retinal eccentricities of 1/6, 1/2, and 5/6 of the retinal radius).

Cell counts were done in duplicate by two investigators.

NADPH-d histochemistry and immunohistochemistry. Six days after ON transection, animals received an overdose of chloral hydrate and were perfused intracardially with 4% PFA in PBS for 10 min. Then, both eyes were dissected and immersion-fixed in 4% PFA for an additional 20 min and then immersed in 30% sucrose in 0.1 M PBS at 4°C for 24 hr. Cryosections were made and collected on gelatin-coated slides, air-dried, and stored at −20°C before further processing. NADPH-d histochemistry was performed as described by Huxlin and Bennett (1995). Briefly, the retina whole mounts or sections were incubated for 2–3 hr at room temperature in a solution of 0.5 mg of nitroblue tetrazo-
lium, 2 mg of β-NADPH, and 6 μl of Triton X-100 in 2 ml of PBS (chemicals purchased from Sigma, Deisenhofen, Germany). The development of the staining was checked by repeated microscopic inspections. The histochemical reaction was stopped by washing three times with PBS. Sections were coverslipped in 1:1 glycerol/PBS. BDNF–vehicle-treated and control retinas were always processed in parallel to avoid variability of the histochemical reaction.

For immunohistochemistry, retinal cryostat sections were preincubated in 10% normal goat serum (NGS) in PBS containing 0.03% Triton X-100 (PBST) for 1 hr at room temperature. The sections were incubated at 4°C overnight with either the primary antibody directed against NOS-I (R-20; diluted 1:250 in 2% NGS–PBST; Santa Cruz Biotechnology, Ismaning, Germany) (Heneka et al., 1998) or primary antibodies directed against tissue macrophages (ED-1), the rat equivalent of the human complement receptor CR-3 (Ox-42), and MHC class II antigen (Ox-6) (diluted 1:100 in 2% NGS–PBST; Serotec, Oxford, England). Omission of the primary antibody served as negative control. Immunoreactivity was visualized by incubating the sections with either goat anti-rabbit IgG or goat anti-mouse IgG serum, respectively, both conjugated with Cy-3 (1:250 in a solution of 10% NGS in PBS; Dianova, Hamburg, Germany) for 1 hr at room temperature. Sections were coverslipped in Mowiol (Hoechst, Frankfurt, Germany). For both NADPH-d reaction and immunohistochemistry, retinal sections of at least three different animals per experimental group were examined.

RT-PCR and Western blot experiments. For RT-PCR experiments, retinas were quickly dissected and immediately snap-frozen in liquid nitrogen. Then, total RNA was extracted using Trizol reagent (Life Technologies GmbH, Karlsruhe, Germany) following the manufacturer’s protocol. RT-PCR was performed according to standard protocols. one μg of total RNA was reverse-transcribed using Maloney murine leukemia virus reverse transcriptase (Life Technologies GmbH) in a 20 μl reaction volume. Two microliters were used as a template for PCR. PCR was performed using 0.6 U of AmpliTaq polymerase (Perkin-Elmer, Branchburg, NJ) in a 50 μl reaction volume containing 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 0.01% gelatin, 2.5 mM MgCl2, 8 mM dNTP, and 1 μM each of forward and reverse primers. Primer sequences are as follows: NOS-I up, 5’-TTCCGAAGCTTCTGGCAAC-3’; NOS-I down, 5’-GGATGGCTTTTGAGGACATC-3’ with annealing temperature of 55°C and 35 amplification cycles run; NOS-II up, 5’-AAGTTTCTTGTGGCAGCAGC-3’; NOS-II down, 5’-CCTCGTGGCTTTGGGCTCCT-3’ with annealing temperature of 54°C and 35 amplification cycles run using the hot-start technique; G3PDH up, 5’-ACCACAGTCCATGCCATCAC-3’; and G3PDH down, 5’-TCCACCACCTTGGTATGG-3’ with annealing temperature of 55°C and 24 amplification cycles run. Five microliters of loading dye were added to the reaction, and 10 μl were analyzed on 1.5% agarose gels containing 0.05% ethidium bromide. We varied the cDNA template concentrations and PCR cycle numbers to control for saturation of the PCR reaction.

For Western blot experiments, retinas were homogenized in lysis buffer containing 50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.1 mM PMSF, and 2 μg/ml pepstatin, leupeptin, and aprotinin, pH 8.3. The cell suspension was lysed on ice for 20 min, and cell debris was pelleted at 14,000 × g for 15 min. The protein concentration of the supernatant was determined using the BCA reagent (Pierce, Rockford, IL). After separation by reducing SDS-PAGE (Ausubel et al., 1987) of the lysates (20 μg of protein per lane), proteins were transferred to a polyvinylidene difluoride membrane and blocked with 5% skim milk in 0.1% Tween 20–PBS (PBS-T). The membranes were incubated with the primary antibodies against NOS-I [1:2000 in 1% skim milk in PBS-T; Transduction Laboratories (Lexington, KY), distributed by Dianova] (Samdani et
RESULTS
Effects of ON transection and intraocular BDNF on retinal NADPH-d reactivity

In unlesioned adult rat retinas, NADPH-d staining was mainly found in a subpopulation of amacrine neurons located at the inner margin of the inner nuclear layer (INL). Within this cell population, we could distinguish two different cell types. The most often observed cell type had a large soma, ranging in size from 12 to 16 μm, and was darkly stained for NADPH-d reactivity (type I), whereas the rare second cell type (type II) was smaller, ranging in size from 6 to 10 μm, and was less intensely stained (Fig. 1). In favorable tissue sections, long processes from type I neurons could be followed into sublaminae b and c of the inner plexiform layer (IPL). Type I neurons were concentrated in the central retina, whereas type II neurons did not show a noticeable preference for a certain retinal eccentricity. The ganglion cell layer (GCL) contained a modest number of rather small cells displaying NADPH-d reactivity (Fig. 2D). Because of their low staining intensity, they could only be observed after incubation of the retinas for >3 hr in the staining solution. Judged by their morphology, these cells most likely represented displaced amacrine neurons (Darius et al., 1995).

Six days after ON transection, we observed an increase in retinal NADPH-d staining (Fig. 1B). Interestingly, RGC axons now displayed NOS histochemical activity, although their somas were spared (Fig. 2D). Furthermore, the staining intensity of the IPL showing a trilaminar staining grew stronger. Vehicle injection on day 4 after axotomy did not elicit a staining pattern different from ON transection alone (data not shown).

However, a single intraocular injection of 500 ng of BDNF on day 4 after axotomy resulted in an increase of NADPH-d staining, which was much more pronounced than the increase induced by...
ON lesion itself. Most strikingly, the staining intensity and the number of amacrine neurons in the INL expressing NADPH-d reactivity increased (Fig. 1D). In most cases, the arborization of the long type I and short type II cell processes in the IPL were visible in sublaminae a and b, respectively. Although the labeling of RGC axons grew stronger, we still did not find RGC somas visible in sublaminae a and b, respectively. Although the labeling of RGC axons grew stronger, we still did not find RGC somas visible in sublaminae a and b, respectively. Although the labeling of RGC axons grew stronger, we still did not find RGC somas visible in sublaminae a and b, respectively. Although the labeling of RGC axons grew stronger, we still did not find RGC somas visible in sublaminae a and b, respectively.

Quantification of the BDNF effects on NADPH-d-reactive neurons in the INL
We quantified cell densities of NADPH-d-positive amacrine neurons in the INL in flat mount preparations (Fig. 3). ON transection alone led to the increase in retinal NADPH-d staining intensity as described above, but the number of NADPH-d-positive amacrine neurons in axotomized retinas did not vary from that in control retinas (Fig. 4). However, a single injection of 500 ng of BDNF 4 d after lesion did not only further increase the staining intensity of this subpopulation of amacrine cells but also increased their number. As has been demonstrated in postnatal rats (Cellerino et al., 1998a), this effect was most noticeable in type II amacrine neurons. Their number increased almost fivefold after BDNF injection. The number of type I cells positive for NADPH-d reactivity, on the other hand, increased only marginally by a factor of 1.2. Vehicle injection failed to mimic the effects of BDNF.

Regulation of retinal NOS mRNA and protein expression after axotomy and intraocular BDNF
To determine whether ON transection and BDNF increased NOS activity in the retina by regulating NOS expression, we performed RT-PCR and Western blot experiments using primers and antibodies specific for the isoforms NOS-I and NOS-II (Fig. 5). We found constitutive expression of NOS-I mRNA and protein in control retinas, which markedly increased 6 d after ON lesion. Additional vehicle or BDNF treatment did not further change NOS-I mRNA or protein expression. Low levels of NOS-II mRNA and barely detectable levels of NOS-II protein were also observed in unlesioned control retinas. Axotomy without or with vehicle treatment did not change retinal NOS-II mRNA or protein expression. However, a single intraocular injection of 500 ng of BDNF on day 4 after ON lesion was found to induce both NOS-II mRNA and protein expression in the retina.

NOS-I immunohistochemistry
In normal control retinas, few type I and type II amacrine neurons in the INL were immunoreactive for NOS-I (Fig. 6A). We further found staining of the IPL typically appearing as a trilaminar pattern. NOS-I immunoreactivity was also detected in a subpopulation of cells in the GCL, which was greater than the one staining for NADPH-d reactivity (Fig. 6A, arrow). To distinguish between RGCs and displaced amacrine neurons, we used retrograde fluorescent tracing to unequivocally identify RGCs. As can be derived from Figure 6F, subpopulations of both RGCs (arrows) and displaced amacrine neurons (arrowhead) showed NOS-I immunoreactivity. RGC axons, however, were not positive for NOS-I (Fig. 6B).

Six days after ON transection, retinal NOS-I immunoreactivity not only increased the staining intensity but also the number of particularly type II amacrine neurons in the INL (Figs. 4B, 6C). The number of NOS-I-immunoreactive type I amacrine neurons did not change after axotomy. The trilaminar staining pattern of the IPL was still preserved but displayed stronger immunoreactivity. In addition to RGC somas, now their axons were immunoreactive for NOS-I to a significantly greater extent than the cell bodies (Fig. 6C, small arrow). However, immunostaining could only be detected within their intraretinal course up to the optic disk (Fig. 6D, arrow). Intraocular injection of vehicle or BDNF after ON transection did not lead to any marked changes in NOS-I immunoreactivity compared with axotomy without treatment (Figs. 4B, 6E).
NMDA antagonism does not prevent the BDNF-induced increase in NADPH-d reactivity

Comparison of the NOS-I immunostainings with the NADPH-d stainings indicated that most of the increase in NOS histochemical activity observed after BDNF treatment could be localized to NOS-I-positive structures. Because we failed to detect an induction of NOS-I mRNA or protein expression by BDNF, however, we assumed that BDNF regulates NOS-I activity post-translationally. In a number of studies, it has been shown that BDNF potentiates glutamatergic neurotransmission, thereby increasing intracellular calcium levels (Jarvis et al., 1997; Sakai et al., 1997). Therefore, we investigated whether BDNF might enhance NOS-I activity via a calcium-dependent mechanism involving NMDA receptors.

To this end, we examined whether simultaneous administration of the NMDA open-channel blocker memantine could reduce the increase in retinal NADPH-d reactivity induced by BDNF. In addition, we addressed the question whether the neuroprotective action of BDNF on axotomized RGCs could be potentiated by
intraocular injections of 500 ng of BDNF repeated on days 4, 7, and 10 after axotomy resulted in survival of 804 ± 87 RGCs/mm². Systemic application of 20 mg/kg memantine neither exerted any significant neuroprotective effect when given alone (412 ± 77 RGCs/mm²) nor significantly potentiated the neurotrophic effect of BDNF when given at a combined treatment regimen (919 ± 54 RGCs/mm²). A more detailed analysis of RGC survival with respect to retinal eccentricity suggested a regional difference in survival rates in response to combined BDNF and memantine treatment versus single BDNF treatment. In the peripheral retina, the combined treatment strategy led to higher RGC survival than single BDNF treatment. However, this difference did not reach statistical significance (p > 0.05).

**BDNF activates microglia**

Attempts to identify the cellular source of NOS-II upregulation after intraocular BDNF injection using several NOS-II antibodies remained unsuccessful because of unspecific background staining. Because CNS microglia and macrophages have been reported to be responsive to neurotrophins (Elkabes et al., 1996), we asked whether the induction of NOS-II was caused by a BDNF-mediated activation of immune-competent cells known to express NOS-II (Nathan and Xie, 1994).

We performed immunohistochemistry using antibodies directed against monocytes–macrophages (ED-1), complement receptor-3 (Ox-42), and MHC-II antigen (Ox-6) to distinguish between macrophages and microglial cells and to determine their state of activation (Ng and Ling, 1997; Watanabe et al., 1999). Independent of the experimental treatment, ED-1-positive cells were not detected. In contrast, we observed few Ox-42-immunoreactive cells and cell processes in unlesioned control retinas (Fig. 8A). They were either located in close proximity of blood vessels or scattered in the outer sublaminae of the IPL with a preference for the central retina. Six days after axotomy without treatment, Ox-42-positive cells not only increased slightly in number but were now also seen in the inner IPL and the GCL (Fig. 8C). Ox-42 expression in vehicle-injected retinas did not differ from only axotomized retinas (Fig. 8E). Still most of the Ox-42-positive cells displayed a ramified phenotype as observed in unlesioned controls. A single injection of BDNF markedly enlarged the population of Ox-42-immunopositive cells, particularly in the central retina (Fig. 8G). They were distributed in all sublaminae of the IPL, in the GCL, and sometimes even visible in the INL and outer plexiform layer (OPL). Ox-6 immunohistochemistry mainly paralleled Ox-42 immunoreactivity, with the exception that we did not detect any Ox-6-positive cells in control tissue (Fig. 8B). Six days after axotomy without or with additional injection of vehicle, few Ox-6-immunoreactive cells with oval- or round-shaped somas appeared in the inner IPL and GCL (Fig. 8D,F). Additional injection of BDNF led to a strong increase in the number of Ox-6-immunoreactive cells, now distributed from the OPL to all sublaminae of the IPL and the GCL. Various phenotypes could be observed, ranging from ramified over rod-shaped to amoeboid morphology (Fig. 8H).

**DISCUSSION**

In the present study, we characterized the effects of ON transection and BDNF on retinal NOS expression and activity. Although ON transection does substantially increase retinal NOS-I expression, it leads only to a rather small increase in NOS activity. Additional application of exogenous BDNF, although not further increasing NOS-I expression, leads to a dramatic post-translational upregulation of NOS-I activity. Furthermore, BDNF induces NOS-II expression, most likely by activating retinal microglia.
In unlesioned control retinas, we found NOS-I-immunoreactive amacrine cells in the inner INL and a modest number of NOS-I-immunoreactive displaced amacrine cells and RGCs in the GCL. These observations are in good agreement with previous studies showing a similar distribution of NOS-I immunoreactivity in the rat retina (Yamamoto et al., 1993). The pattern of NADPH-d staining corresponds well with NOS-I immunoreactivity, suggesting that retinal NOS activity is mainly active in the neuronal isofrom. The only two exceptions to this were (1) the photoreceptor segments that were NADPH-d-reactive but not NOS-I-immunoreactive (Koistinaho and Sagar, 1995) and (2) a subpopulation of RGCs that we found to be NOS-I-immunoreactive without showing NADPH-d reactivity. The small population of NADPH-d-positive cells we observed in the GCL were by morphology rather displaced amacrine cells than RGCs. ON transection induced an increase in retinal NOS-I expression as we could demonstrate by RT-PCR and Western blot analysis. Retinal NOS-I immunoreactivity also increased in that we observed a greater number of type II amacrine neurons in the INL and a higher overall staining intensity of labeled cells and the IPL. Besides RGC somas, to an even greater extent, their axons also became immunoreactive. NADPH-d reactivity, however, only increased in the IPL and in RGC axons, still sparing the RGC somas. Thus, there seem to exist tools to specifically target NOS-I activity to certain subcellular locations. The ways how neurons target NOS-I protein to specific subcellular locations are just beginning to be identified. The N-terminal domain of NOS-I, for example, contains a PDZ binding motif that is found in a diverse group of cytoskeletal proteins (Cho et al., 1992). It is known that NOS-I interacts with the postsynaptic density protein PSD-95, which leads to a close association of NOS-I and the NMDA receptor in the postsynapse (Brenman et al., 1996; Brenman and Bredt, 1997). Another example of subcellular targeting of NOS protein has been discovered for the third isofrom. NOS-III phosphorylation results in a translocation from the membrane to the cytosol (Michel et al., 1993). In our study, however, we did not only find a higher expression of NOS-I protein in RGC axons, but we also observed a specific targeting of its activity to axons sparing the RGC somas. One could speculate whether a localized expression of the protein inhibitor of neuronal NOS (PIN) prevents dimerization of NOS-I (Jaffrey and Snyder, 1996), suppresses NOS-I activity in RGC somas.

Despite its constitutive expression, it has been repeatedly described that NOS-I protein and its activity can be subject to dramatic upregulation in axotomized neurons in both the CNS and PNS (for review, see Garthwaite and Boulton, 1995). It still remains unclear, however, whether such regulation of NOS is causally involved in neuronal death after axotomy, whether it is just an epiphenomenon, or whether it has even a neuroprotective role (Verge et al., 1992; Yu, 1994; Huxlin and Bennett, 1995; Rossiter et al., 1996). Although NOS expression increases after ON transection, the overall changes in retinal NOS histochemical activity after ON transection that we and others have found are rather small (Huxlin and Bennett, 1995). Therefore, we favor the hypothesis that NO is not a major cause of cell death of axotomized RGCs, which is supported by our previous results showing that the NOS inhibitor L-NAME by itself was ineffective in promoting the survival of axotomized RGCs (Klöcker et al., 1998). It is worth noting that lesion-induced NOS-I protein regulation was not only found in axons of RGCs, which are the cells directly affected by ON transection, but also in neurons of other retinal cell layers that were not lesioned. We have to postulate, therefore, that RGCs communicate retrogradely with their input neurons. The nature of this retrograde messenger system, however, remains speculative.

Intraocular injection of BDNF did not produce the same qualitative changes in the expression of NOS-I mRNA or protein compared with axotomy alone as verified by RT-PCR, Western blot, and immunohistochemistry. However, we observed a strong increase in NADPH-d activity after BDNF treatment, which could be localized to NOS-I-immunoreactive tissue. Most likely, this can be explained by a post-translational regulation of NOS-I activity. Because BDNF can increase intracellular calcium levels by enhancing glutamatergic neurotransmission (Jarvis et al., 1997; Sakai et al., 1997) and because NMDA receptors are expressed in the INL and GCL of the retina (Brandstätter et al., 1994; Hartveit and Veruki, 1997), we tested whether simultaneous application of an NMDA antagonist could reduce the upregula-
tion of retinal NOS activity by BDNF and whether it could improve BDNF neuroprotection on axotomized RGCs as a specific NOS inhibitor had done before (Klöcker et al., 1998). Systemic application of memantine neither changed the upregulation of NOS activity induced by BDNF nor significantly potentiated the neuroprotective effects of BDNF. This is probably not attributable to a dosage problem, because we used the highest dose described in the literature predicted to provide substantial neuroprotection in models of ischemia and glutamate toxicity when given intraperitoneally (Seif el Nasr et al., 1990; Block and

Figure 8. BDNF activates retinal microglia. Complement receptor-3 (Ox-42; left column) and MHC-II antigen (Ox-6; right column) immunoreactivity is shown in radial sections of untreated control retinas (A, B) and of retinas 6 d after ON transection either without treatment (C, D) or with a single injection of vehicle (E, F) or 500 ng of BDNF (G, H) on day 4 after lesion. ONL, Outer nuclear layer. Scale bar, 45 μm.
Schwarz, 1996; Vorwerk et al., 1996; Lagreze et al., 1998; Osborne, 1999). We can also exclude possible toxic effects of memantine because of high dosage, because both single memantine treatment and the combination of BDNF and memantine did not result in lower, but even slightly higher, RGC rescue compared with controls. These results therefore strongly suggest that enhancement of NMDA receptor-mediated neurotransmission is not the mechanism by which BDNF post-translationally regulates retinal NOS-I activity. Besides modifying NMDA receptors, BDNF could use many other ways to increase intracellular calcium, such as by increasing its release from intracellular stores (Roback et al., 1995; Finkbeiner et al., 1997). Alternatively, a modification of AMPA receptors, also known to be expressed in the INL and GCL and to have rather high calcium conductances (Hamassaki Britto et al., 1993; Rorig and Grantyn, 1993), is conceivable. That single memantine treatment did not result in significant rescue of axotomized RGCs is in contrast to neuro-protective effects of the NMDA antagonist MK-801 on the β subpopulation of RGCs after ON transection in cats (Russelakis Carneiro et al., 1996) but in good agreement with experiments in rats demonstrating even adverse effects of MK-801 on the survival of axotomized RGCs (Schmitt and Sabel, 1996).

In addition to upregulation of NOS-I activity, intraocular application of BDNF induced NOS-II expression as detected by RT-PCR and Western blot experiments. Unfortunately, we were not able to localize the cellular source of NOS-II expression in the retina by immunohistochemistry. However, our data support the hypothesis that BDNF activates immune-competent cells known to express NOS-II (Garthwaite and Boulton, 1995). Although we have never found any macrophages in retinas of any experimental group, we observed few Ox-42-positive microglial cells, even in unlesioned retinas. Six days after ON transection, their number markedly increased, and they translocated into the GCL, now displaying phagocytic activity as revealed by their morphology and Ox-6 immunoreactivity. This observation can easily be explained by the induction of apoptotic cell death among RGCs, which starts at approximately day 4 and reaches a maximum on day 7 after ON lesion (Garcia-Valenzuela et al., 1994; Isenmann et al., 1997). Additional application of BDNF further stimulated the microglial response, which is in good agreement with in vitro data showing that CNS microglia produces and responds to neurotransphins (Condorelli et al., 1995; Elkabes et al., 1996; Miwa et al., 1997). Indeed, the observed microglial activation in our model does not have to be a direct response to activation of the BDNF receptor TrkB or the low-affinity neurotrophin receptor p75 but could alternatively be an indirect response to BDNF-induced changes in the retina. Moreover, further studies are needed to actually prove that BDNF upregulates NOS-II expression in microglial cells, because our results do not exclude that retinal neurons normally expressing only NOS-I can additionally upregulate NOS-II in response to BDNF. We detected a basal expression of NOS-II in control tissue, which could be explained by the small population of resting microglial cells we observed also in unlesioned controls. Alternatively, blood cells remaining in retinal vessels during tissue preparation could account for that observation.

In the CNS, NO has highly diverse functions, being involved in neuronal communication, host defense, and vascular regulation (Nathan, 1992; Nathan and Xie, 1994; Schmidt and Walter, 1994; Yun et al., 1996), even exerting neuroprotective effects by inhibiting apoptosis (Melino et al., 1997; Ogura et al., 1997; So et al., 1998) but also being neurotoxic in various CNS disease conditions (Gross and Wolin, 1995; Iadecola, 1997). Besides the redox state of NO, its concentration and the kinetics of its formation often determine the quality of its action. Because NOS-I depends on intracellular calcium, it can produce NO in small and highly regulated bursts well suited for its physiological functions (Garthwaite and Boulton, 1995). NOS-II, however, is independent of calcium and can produce large amounts of NO continuously for long periods of time, which probably add to the cytotoxic effects of NO (Gross and Wolin, 1995). Future studies will have to reveal whether the differential effects of BDNF on the NOS isoforms we described contribute to different extents to the adverse effect limiting BDNF neuroprotection (Klöcker et al., 1998). Then, the development of feasible strategies for isoform-specific inhibition of NOS in vivo could be useful to potentiate BDNF neuroprotection more powerfully and less afflicted with side effects.

REFERENCES


